Clinical Trials Logo
  1. Home
  2. Liver Neoplasm
  3. NCT04702230

Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization

Liver Neoplasm Clinical Trial

Official title:
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization

Clinical Trial Summary

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is commonly treated with transarterial locoregional therapies (transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)). Early assessment of the effectiveness of transarterial locoregional therapies is critical for treatment planning and early identification of non-responders to allow a timely repeat treatment or conversion to a second-line local-regional or systemic treatment. Response of HCC to transarterial locoregional therapies is usually assessed by changes in tumor contrast material enhancement thought to reflect tumor viability. However, contrast material enhancement may not always accurately indicate tumor response as it may also reflect reactive changes rather than residual tumor tissue. A potential alternative for evaluation of the residual tumor is diffusion-weighted imaging (DWI), which can differentiate between tumor tissue with high cellularity and tumor necrosis. DWI has been shown useful in therapy response assessment of liver tumors. A further development of DWI is intravoxel incoherent motion imaging (IVIM), an MRI technique which also takes tumor perfusion and thus tumor viability into account. This makes IVIM a promising tool for early therapy response assessment in HCC patients. The primary objective is to proof that DWI and especially IVIM with its inherent perfusion information related to tumor neovascularization allows for reliable and quantitative monitoring of tumor response and separating responders from non-responders to either of the two locoregional treatments (TACE or TARE) The secondary objective is to identify whether DWI/IVIM acquired during early follow-up (1 month after treatment) leads to better response assessment than DWI/IVIM acquired during later follow-up (3 months after treatment). The primary outcome will be the DWI/IVIM values in patients responding to transarterial locoregional therapies of HCC compared to patients not responding to therapy according to mRECIST at 6 months The secondary outcome will be the number of patients correctly identified as responders at early follow-up (after 1 month) with DWI/IVIM compared to the number of patients correctly identified as resopnders at later follow-up (after 3 months).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04702230
Study type Observational
Source University of Zurich
Contact
Status Terminated
Phase
Start date September 11, 2017
Completion date April 30, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Active, not recruiting NCT01217034 - Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib Phase 2
Recruiting NCT05169177 - Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Withdrawn NCT02599909 - Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
Terminated NCT03998033 - Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma Phase 1
Recruiting NCT04010071 - Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors Phase 2
Recruiting NCT04864054 - T-Cell Therapy (ECT204) in Adults With Advanced HCC Phase 2
Terminated NCT04187937 - Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections N/A
Completed NCT02471313 - Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization Phase 2
Completed NCT00001576 - A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver Phase 1
Recruiting NCT01542281 - Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer N/A
Recruiting NCT03803436 - Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation Phase 2
Completed NCT05495529 - Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
Recruiting NCT02632864 - Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial Phase 2
Completed NCT02571946 - Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis N/A
Not yet recruiting NCT01180088 - Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy N/A
Withdrawn NCT00510627 - Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases Phase 4
Completed NCT05848947 - SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Phase 4
Not yet recruiting NCT05723705 - Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
Terminated NCT04502082 - Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) Phase 1/Phase 2